PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Breakthrough in COPD research • COPD: An overview PART 05: Pipeline analysis PART 06: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 07: Key buying criteria for COPD drugs PART 08: Market segmentation by drug class • Combination therapies • Bronchodilators • Steroids • Leukotriene antagonists • PDE-4 inhibitors • Other medications PART 09: Segmentation by ROA • Inhalation • Oral PART 10: Drug delivery devices market for COPD drugs • Market overview • Market segmentation by product type PART 11: Geographical segmentation • Global COPD drugs market by geography 2015-2020 • COPD drugs market in Americas • COPD drugs market in EMEA • COPD drugs market in APAC • COPD drugs market in China PART 12: Market drivers • Increase in smoking prevalence • Uptake of LABA/LAMA combination therapies • Robust pipeline with tentative approval of drugs PART 13: Impact of drivers PART 14: Market challenges • Lack of innovation in pipeline molecules • Negligence toward use of controller medications • Low diagnosis rates PART 15: Impact of drivers and challenges PART 16: Market trends • Innovative technologies for drug delivery • Increased adoption of e-cigarettes and smoking cessation products • Emergence of ultrasonic nebulizers • Increase in online marketing services • Growing use of home healthcare devices PART 17: Vendor landscape • Competitive scenario • Key news PART 18: Key vendor analysis • AstraZeneca • Boehringer Ingelheim • GSK • Novartis • Teva Pharmaceuticals • Other prominent vendors PART 19: Appendix • List of abbreviations PART 20: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Breakthrough research activities in field of COPD Exhibit 03: Percentage share of pipeline molecules based on stage of development Exhibit 04: Pipeline molecules based on MOA and stage of development Exhibit 05: Percentage share of pipeline drugs based on MOA Exhibit 06: Global COPD drugs market 2015-2020 ($ billions) Exhibit 07: Global COPD drugs market snapshot: Developed and emerging markets 2015 Exhibit 08: Global COPD drugs market: Key parameters driving the market 2015 Exhibit 09: Five forces analysis Exhibit 10: Key buying criteria for COPD drugs Exhibit 11: Impact of key customer segments on global COPD drugs market Exhibit 12: Segmentation of COPD drugs based on drug class Exhibit 13: Percentage share of global COPD drugs by drug class based on revenue 2015 Exhibit 14: Global COPD drugs market: Drug class segmentation growth cycle analysis 2015 Exhibit 15: Combination therapies market in global COPD drugs market 2015-2020 ($ billions) Exhibit 16: Bronchodilators market in global COPD drugs market 2015-2020 ($ billions) Exhibit 17: Steroid drugs market in global COPD drugs market 2015-2020 ($ billions) Exhibit 18: Leukotriene antagonists market in global COPD drugs market 2015-2020 ($ billions) Exhibit 19: YoY growth and revenue of Daliresp 2012-2015 ($ billions) Exhibit 20: Global COPD drugs market segmentation by drug class 2015 Exhibit 21: Segmentation of global COPD drugs market by ROA Exhibit 22: Global COPD drug delivery devices market 2015-2020 ($ millions) Exhibit 23: Global COPD devices market segmentation by product type Exhibit 24: Percentage share of global COPD drug delivery devices by type 2015 Exhibit 25: Percentage share of inhalers in global COPD drug delivery devices market 2015 Exhibit 26: Inhalers market in global COPD drug-devices market 2015-2020 ($ millions) Exhibit 27: Percentage share of nebulizers in global COPD drug delivery devices market by technology 2015 Exhibit 28: Nebulizers market in global COPD drug-devices market 2015-2020 ($ millions) Exhibit 29: Global COPD drugs market by geography 2015-2020 Exhibit 30: Percentage share of global COPD drugs market by geography 2015 and 2020 Exhibit 31: Global COPD drugs market segmentation by geography 2015-2020 ($ billions) Exhibit 32: Global share of COPD drugs market by geography 2015 Exhibit 33: COPD drugs market in Americas 2015-2020 ($ billions) Exhibit 34: Prevalence rates of COPD in few countries of EMEA Exhibit 35: COPD drugs market in EMEA 2015-2020 ($ billions) Exhibit 36: COPD drugs market in APAC 2015-2020 ($ billions) Exhibit 37: COPD drugs market in China 2015-2020 ($ billions) Exhibit 38: Global COPD drugs market: Country analysis based on revenue and growth rate Exhibit 39: Drug approvals in COPD drugs market in past three years (2014-2016) Exhibit 40: Few COPD drug molecules in registration stage Exhibit 41: Impact of drivers Exhibit 42: Controller and rescue medications for the treatment of COPD Exhibit 43: Impact of drivers and challenges Exhibit 44: Key vendors ranking 2015 Exhibit 45: Market share of key vendors based on revenues 2015 Exhibit 46: Geographical presence of key vendors Exhibit 47: Competitive scenario of global COPD drugs market vendors 2015-2020 Exhibit 48: AstraZeneca: YoY revenue and growth rate of Symbicort 2013-2015 ($ billions) Exhibit 49: AstraZeneca: Geographical segmentation of Symbicort 2015 Exhibit 50: AstraZeneca: YoY revenue and growth rate of Pulmicort 2013-2015 ($ millions) Exhibit 51: AstraZeneca: Geographical segmentation of Pulmicort 2015 Exhibit 52: AstraZeneca: Metrics analysis Exhibit 53: Boehringer Ingelheim: YoY revenue and growth rate of Spiriva 2013-2015 ($ billions) Exhibit 54: Boehringer Ingelheim: Metrics analysis Exhibit 55: GSK: YoY revenue and growth rate of Seretide/Advair 2013-2015 ($ billions) Exhibit 56: Geographical segmentation of Seretide/Advair 2015 Exhibit 57: GSK: YoY revenue and growth rate of Flixotide/Flovent 2013-2015 ($ billions) Exhibit 58: GSK: Geographical segmentation of Flixotide/Flovent 2015 Exhibit 59: GSK: YoY revenue and growth rate of Ventolin 2013-2015 ($ billions) Exhibit 60: GSK: Geographical segmentation of Ventolin 2015 Exhibit 61: GSK: YoY growth and revenue of Relvar/Breo Ellipta 2014-2015 ($ millions) Exhibit 62: GSK: Geographical segmentation of Relvar/Breo Ellipta 2015 Exhibit 63: GSK: YoY growth and revenue of Anoro Ellipta 2014-2015 ($ millions) Exhibit 64: GSK: Geographical segmentation of Anoro Ellipta 2015 Exhibit 65: GSK: Metrics analysis Exhibit 66: Novartis: YoY revenue and growth rate of Onbrez Breezhaler/Arcapta Neohaler 2014-2015 ($ millions) Exhibit 67: Novartis: YoY revenue and growth rate of Seebri Breezhaler 2013-2015 ($ millions) Exhibit 68: Novartis: YoY revenue and growth rate of Ultibro Breezhaler 2013-2015 ($ millions) Exhibit 69: Novartis: Metrics analysis Exhibit 70: Teva Pharmaceuticals: YoY revenue and growth rate of ProAir 2013-2015 ($ millions) Exhibit 71: Teva Pharmaceuticals: YoY revenue and growth rate of Qvar 2013-2015 ($ millions) Exhibit 72: Teva Pharmaceuticals: Metrics analysis

AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, Asmacure, Astellas Pharma, BioMarck Pharmaceuticals, Chiesi Farmaceutici, Cytokinetics, F. Hoffmann-La Roche, Gilead Sciences, Innoviva, Invion, MediciNova, Mereo BioPharma, Mylan, Orion Corporation, Palobiofarma, Pearl Therapeutics, Pharmaxis, Prosonix, Pulmagen Therapeutics, RespiVert, SolAeroMed, Sunovion Pharmaceuticals, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention , Yungjin Pharm, ZAI Lab.